Word: cardiovascular
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...levels appear to be beneficial to Parkinson’s patients, Weisskopf said it would be unwise to tell patients to increase their urate levels by diet or supplement, as high levels of urate can lead to gout, increased mortality by up to 20 percent, and negative kidney and cardiovascular symptoms...
...likely to have an adverse effect on the heart," says Dr. JoAnn Manson, chief of preventive medicine at Harvard's Brigham and Women's Hospital and an author of the study. "But it does not mean that women should begin taking estrogen for the express purpose of preventing cardiovascular events because there are other risks of hormone therapy...
...population is so vulnerable to heart disease, anything that increases their risk of heart attacks is "worrisome" and warrants further study. Nissen tells TIME that he started looking into Avandia because he was concerned by the data in two of the largest studies of patients taking the drug. "The cardiovascular events were all going the wrong direction," he says. Though the results weren't statistically significant, they pushed him to look at other data sets, including studies by the FDA and from the clinical-trials registry on GlaxoSmithKline's website. Nissen had gathered his data by April...
...results of Nissen's research were troubling enough that the Journal, in an editorial accompanying his article, concluded that "the rationale for prescribing rosiglitazone at this time is unclear." The cardiovascular risks simply outweigh any benefit the drug appears to give in treating diabetes, the editorial says, and the FDA should now take regulatory action. With more than 1.5 million new cases of Type 2 diabetes each year in the U.S. and Avandia a mainstay in their treatment, 60 million prescriptions have been written since the drug was introduced...
...called "a potential safety issue related to Avandia," issuing a safety alert on the drug just hours after Nissen's study was made public. While the agency pointed out that other studies of the drug have reached different conclusions, it nonetheless will take up the issue of the cardiovascular risk of Avandia and similar drugs with an advisory committee "as soon as one can be convened." Earlier data about Avandia prompted the FDA to strengthen the drug's warning label last year. The FDA also disclosed that GSK recently provided its own meta-analysis of Avandia patients, which found...